Government ❯ Politics ❯ Healthcare Policy

Drug Pricing

Trump Administration Prescription Drug Costs Most Favored Nation Policy Pharmaceutical Industry Medicare Medicare and Medicaid Most Favored Nation Pricing Medicare Negotiations Medicaid Executive Orders Tariffs Pharmaceutical Regulations Affordable Care Act Most-Favored-Nation Pricing Most-Favored-Nation Policy Pfizer Deal Pfizer TrumpRx U.S. Government AstraZeneca Agreement Fertility Services Fertility Drug Pricing GLP-1 Medications Medicare Coverage Prescription Medications Eli Lilly Agreement Biden Administration Medicare Negotiation Pharmaceutical Agreements Inflation Reduction Act Pharmacy Benefit Managers Generic Drugs Pharmaceutical Regulation Pharmaceutical Pricing Regulatory Actions Pharmaceutical Companies Biopharmaceutical Companies Pharmaceuticals Pharmaceutical Economics

Trump Touts 'Affordability President' Rebrand, Claims Drug Prices Fell 500%–700%

Fact-checkers say the 500%–700% figures lack evidence, with confirmed drug‑price cuts to date limited to specific products and programs.

White House Clinches GLP-1 Price Deal as Lilly Sets Zepbound and Pill Pricing

U.S. Strikes Price-Cut Deals With Novo Nordisk and Eli Lilly for GLP‑1s, With Medicare Pilot in 2026

Oz Defends Trump’s Drug-Price Math on NBC as Fact-Checks Reject Claims of Cuts Over 100 Percent

Eli Lilly Raises 2025 Outlook as Tirzepatide Sales Soar, Orforglipron Misses Marks

Pfizer Beats Q2 Estimates and Raises 2025 Profit Forecast